We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regeneron Pharmaceuticals and Vir Biotechnology said they will soon begin clinical trials of monoclonal antibodies they hope will be able to prevent or treat COVID-19 patients. Read More
Results from preliminary research show that AstraZeneca’s blood cancer treatment Calquence (acalabrutinib) provides a benefit in hospitalized COVID-19 patients. Read More
The UK’s Drug Safety Research Unit (DSRU), a nonprofit that studies the safety of medicines, has published the first benefit-risk analysis for Gilead Sciences’ antiviral remdesivir, finding that it has a favorable overall profile, although questions remain about the drug’s safety. Read More
AbbVie has entered into a partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapy for COVID-19. Read More
A Texas study of convalescent plasma as a treatment for critically ill COVID-19 patients found the blood-based treatment to be safe for severely infected patients. Read More
AstraZeneca and Accent Therapeutics have teamed up to develop cancer therapies using RNA-modifying proteins in a deal potentially worth more than $1 billion for the small Massachusetts-based startup. Read More